Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015and further to our earlier intimation dated February 06, 2024 and September 04, 2025, we wish toinform you that post the successful validation of batches by our European partner, commercialproduction at Phase 1 of cGMP-4 plant at Dewas has commenced today.
NAVINFLUOR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved in line with Nifty Smallcap 250 and 0.2 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Navin Fluorine International has started commercial production at Phase 1 of its new cGMP-4 facility at Dewas, effective December 31, 2025. This follows successful validation of batches by the company's European partner. The company had earlier intimated the project on February 6, 2024, and provided an update on September 4, 2025. cGMP (current Good Manufacturing Practice) compliance is a key requirement for supplying pharmaceutical-grade fluorinated intermediates to global pharma customers.
Positive for shareholders — commissioning of the new cGMP-4 plant expands production capacity for high-value, regulated fluorinated intermediates, which should support revenue growth and margin expansion as Phase 1 volumes ramp up. The validation by a European partner signals readiness to serve regulated export markets.